Transport characteristics of peptides and peptidomimetics:: I.: N-methylated peptides as substrates for the oligopeptide transporter and P-glycoprotein in the intestinal mucosa

被引:26
作者
Gao, J
Sudoh, M
Aubé, J
Borchardt, RT
机构
[1] Univ Kansas, Dept Pharmaceut Chem, Lawrence, KS 66047 USA
[2] Univ Kansas, Dept Med Chem, Lawrence, KS 66045 USA
来源
JOURNAL OF PEPTIDE RESEARCH | 2001年 / 57卷 / 04期
关键词
Caco-2; cells; N-methylated peptides; oligopeptide transporter; P-glycoprotein; transport;
D O I
10.1046/j.1397-002X.2001.00000.x
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Peptides and peptidomimetics often exhibit poor oral bioavailability due to their metabolic instability and low permeation across the intestinal mucose. N-Methylation has been used successfully in peptide-based drug design in an attempt to improve the metabolic stability of a peptide-based lead compound. However, the effect of N-methylation on the absorption of peptides through the intestinal mucosa is not well understood, particularly when transporters, i.e. the oligopeptide transporter (OPT) and P-glycoprotein (P-gp), modulate the passive diffusion of these types of molecules. To examine this, terminally free and terminally modified (N-acetylated and C-amidated) analogs of H-Ala-Phe-Ala-OH with N-methyl groups on either the Ala-Phe or Phe-Ala peptide bond were synthesized. Transport studies; using Caco-2 cell monolayers, an in vitro model of the intestinal mucosa, showed that N-methylation of the Ala-Phe peptide bond of ft-Ala-Phe-Ala-OH stabilized the molecule to protease degradation, and the resulting analog exhibited significant substrate activity for OPT. However, N-methylation of the Phe-Ala peptide bond of H-Ala-Phe-Ala-OH did not stabilize the molecule to protease degradation, and the substrate activity of the resulting molecule for OPT could not be determined. Interestingly, N-methylation of the Phe-Ata peptide bond of the terminally modified tripeptide Ac-Ala-Phe-Ala-NH2 decreased the substrate activity of the molecule for the efflux transporter P-gp. In contrast, N-methylation of the Ala-Phe peptide bond of the terminally modified tripeptide Ac-Ala-Phe-Ala-NH2 increased the substrate activity of the molecule for P-gp.
引用
收藏
页码:316 / 329
页数:14
相关论文
共 31 条
[1]   EVIDENCE FOR A POLARIZED EFFLUX SYSTEM IN CACO-2 CELLS CAPABLE OF MODULATING CYCLOSPORINE-A TRANSPORT [J].
AUGUSTIJNS, PF ;
BRADSHAW, TP ;
GAN, LSL ;
HENDREN, RW ;
THAKKER, DR .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1993, 197 (02) :360-365
[2]  
Bailey PD, 2000, ANGEW CHEM INT EDIT, V39, P506
[3]  
Bodanszky M., 1994, The Practice of Peptide Synthesis, V2nd
[4]  
BURTON PS, 1992, J CONTROL RELEASE, V19, P87, DOI 10.1016/0168-3659(92)90067-2
[5]   In vitro permeability of peptidomimetic drugs: The role of polarized efflux pathways as additional barriers to absorption [J].
Burton, PS ;
Goodwin, JT ;
Conradi, RA ;
Ho, NFH ;
Hilgers, AR .
ADVANCED DRUG DELIVERY REVIEWS, 1997, 23 (1-3) :143-156
[6]   Design of a potent combined pseudopeptide endothelin-A/endothelin-B receptor antagonist, Ac-DBhg(16)-Leu-Asp-Ile-[NMe]Ile-Trp(21) (PD 156252): Examination of its pharmacokinetic and spectral properties [J].
Cody, WL ;
He, JX ;
Reily, MD ;
Haleen, SJ ;
Walker, DM ;
Reyner, EL ;
Stewart, BH ;
Doherty, AM .
JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (14) :2228-2240
[7]   THE INFLUENCE OF PEPTIDE STRUCTURE ON TRANSPORT ACROSS CACO-2 CELLS .2. PEPTIDE-BOND MODIFICATION WHICH RESULTS IN IMPROVED PERMEABILITY [J].
CONRADI, RA ;
HILGERS, AR ;
HO, NFH ;
BURTON, PS .
PHARMACEUTICAL RESEARCH, 1992, 9 (03) :435-439
[8]   Applications of the Caco-2 model in the design and development of orally active drugs: Elucidation of biochemical and physical barriers posed by the intestinal epithelium [J].
Gan, LSL ;
Thakker, DR .
ADVANCED DRUG DELIVERY REVIEWS, 1997, 23 (1-3) :77-98
[9]  
GANAPATHY V, 1983, J BIOL CHEM, V258, P4189
[10]   UPTAKE AND TRANSEPITHELIAL TRANSPORT OF THE ORALLY ABSORBED CEPHALOSPORIN CEPHALEXIN, IN THE HUMAN INTESTINAL-CELL LINE, CACO-2 [J].
GOCHOCO, CH ;
RYAN, FM ;
MILLER, J ;
SMITH, PL ;
HIDALGO, IJ .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1994, 104 (03) :187-202